Hormone treatment-related adverse events (HTR AEs) with darolutamide (DARO) in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC) from the phase 3 ARAMIS study

被引：0

作者：

Fizazi, K. ^{[1
]}

Shore, N. ^{[2
]}

Smith, M. ^{[3
]}

Carles, J. ^{[4
]}

Lebret, T. ^{[5
]}

Lietuvietis, V. ^{[6
]}

Mahammedi, H. ^{[7
]}

Rannikko, A. ^{[8
]}

Vjaters, E. ^{[9
]}

Werbrouck, P. ^{[10
]}

Miskic, M. ^{[11
]}

Kuss, I. ^{[12
]}

Le Berre, M. ^{[13
]}

Borghesi, G. ^{[14
]}

Sarapohja, T. ^{[15
]}

Fayerabend, S. ^{[16
]}

机构：

[1] Univ Paris Saclay, Inst Gustave Roussy, Dept Canc Med, Paris, France

[2] Carolina Urol Res Ctr, Atlant Urol Clin, Myrtle Beach, SC USA

[3] Massachusetts Gen Hosp, Genitourinary Canc Ctr, Boston, MA 02114 USA

[4] Vall dHebron Inst Oncol, Dept Oncol, Barcelona, Spain

[5] Hosp FOCH, Dept Urol & Renal Transplantat, Suresnes, France

[6] Riga Eastern Clin Univ Hosp, Urol Clin, Riga, Latvia

[7] Jean Perrin Ctr, Dept Med Oncol, Clermont Ferrand, France

[8] Helsinki Univ Hosp Comprehens Canc Ctr, Dept Urol, Helsinki, Finland

[9] P Stradins Clin Univ Hosp, Urol Ctr, Riga, Latvia

[10] AZ Groeninge, Urol Ctr, Kortrijk, Belgium

[11] Bayer Consumer Care AG, Dept Oncol, Basel, Switzerland

[12] Bayer AG, Dept Clin Dev Oncol, Berlin, Germany

[13] Bayer Healthcare SAS, Dept Clin Stat, Loos, France

[14] Bayer AG, Dept TA Oncol, Berlin, Germany

[15] Orion Corp, Orion Pharma, Espoo, Finland

[16] Studienpraxis Urol, Dept Urooncol, Nuertigen, Germany

来源：

EUROPEAN UROLOGY | 2021年 / 79卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

P1226

引用

页码：S1740 / S1741

页数：2

共 50 条

[41] Final survival results from SPARTAN, a phase III study of apalutamide (APA) versus placebo (PBO) in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC).
Jay Small, Eric
Saad, Fred
Chowdhury, Simon
Oudard, Stephane
Hadaschik, Boris A.
Graff, Julie N.
Olmos, David
Mainwaring, Paul N.
Lee, Ji Youl
Uemura, Hiroji
De Porre, Peter
Smith, Andressa
Doris Brookman-May, Sabine
Li, Susan
Zhang, Ke
Brendan Rooney, Oliver
Lopez-Gitlitz, Angela
Raymond Smith, Matthew
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[42] Efficacy and Safety of Darolutamide in Patients with Nonmetastatic Castration-resistant Prostate Cancer Stratified by Prostate-specific Antigen Doubling Time: Planned Subgroup Analysis of the Phase 3 ARAMIS Trial
Boegemann, Martin
Shore, Neal D.
Smith, Matthew R.
Tammela, Teuvo L. J.
Ulys, Albertas
Vjaters, Egils
Polyakov, Sergey
Jievaltas, Mindaugas
Luz, Murilo
Alekseev, Boris
Lebret, Thierry
Schostak, Martin
Verholen, Frank
Le Berre, Marie-Aude
Srinivasan, Shankar
Ortiz, Jorge
Mohamed, Ateesha F.
Sarapohja, Toni
Fizazi, Karim
EUROPEAN UROLOGY, 2023, 83 (03) : 212 - 221
[43] SPARTAN, a phase 3 double-blind, randomized study of apalutamide versus placebo in patients with nonmetastatic castration-resistant prostate cancer (nmCRPC)
Hadaschik, B. A.
Small, E. J.
Saad, F.
Chowdhury, S.
Graff, J. N.
Olmos, D.
Mainwaring, P. N.
Uemura, H.
Lopez-Gitlitz, A.
Trudel, G. C.
Espina, B. M.
Shu, Y.
Park, Y. C.
Rackoff, W. R.
Yu, M. K.
Smith, M. R.
ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 43 - 43
[44] Efficacy and safety of darolutamide in patients with nonmetastatic castration-resistant prostate cancer (nmCRPC) and a prostate-specific antigen doubling time (PSADT) > and ≤ 6 months
Schostak, Martin
Boegemann, Martin
Smith, Matthew R.
Shore, Neal D.
Tammela, Teuvo L. J.
Ulys, Albertas
Vjaters, Egils
Polyakov, Sergey
Jievaltas, Mindaugas
Luz, Murilo
Alekseev, Boris
Kuss, Iris
Le Berre, Marie-Aude
Snapir, Amir
Sarapohja, Toni
Fizazi, Karim
ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 3) : 105 - 105
[45] Association of local progression with deterioration of urinary symptoms and occurrence of genitourinary adverse events (AEs) in nonmetastatic Castration-Resistant Prostate Cancer (nmCRPC): Post hoc analysis of PROSPER
Grimm, M-O.
Hussain, M.
Stenzl, A.
Todenhoefer, T.
Haas, G. P.
Sugg, J.
Brauner, R.
Gross-Langenhoff, M.
Sternberg, C. N.
EUROPEAN UROLOGY, 2021, 79 : S1738 - S1739
[46] Identifying molecular determinants of response to apalutamide (APA) in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC) in the SPARTAN trial.
Feng, Felix Y.
Thomas, Shibu
Gormley, Michael
Lopez-Gitlitz, Angela
Yu, Margaret K.
Cheng, Shinta
Ricci, Deborah S.
Rooney, Oliver Brendan
Mainwaring, Paul N.
Olmos, David
Saad, Fred
Chowdhury, Simon
Hadaschik, Boris A.
Fishbane, Nicholas
Davicioni, Elai
Liu, Yang
Small, Eric Jay
Smith, Matthew Raymond
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
[47] RESPONSE TO APALUTAMIDE (APA) AMONG PATIENTS (PTS) WITH NONMETASTATIC CASTRATION-RESISTANT PROSTATE CANCER (NMCRPC) FROM SPARTAN BY DECIPHER GENOMIC CLASSIFIER (GC) SCORE
Saad, Fred
Thomas, Shibu
Feng, Felix Y.
Gormley, Michael
Lopez-Gitlitz, Angela
Yu, Margaret K.
Cheng, Shinta
Ricci, Deborah S.
Rooney, Oliver Brendan
Mainwaring, Paul N.
Olmos, David
Chowdhury, Simon
Hadaschik, Boris A.
Fishbane, Nick
Davicioni, Elai
Liu, Yang
Small, Eric J.
Smith, Matthew R.
JOURNAL OF UROLOGY, 2019, 201 (04): : E216 - E216
[48] Overall survival (OS) results of phase III ARAMIS study of darolutamide added to androgen deprivation therapy (ADT) for non-metastatic castration-resistant prostate cancer (nmCRPC)
Krieger, Laurence
Fizazi, Karim
Shore, Neal
Tammela, Teuvo L.
Ulys, Albertas
Vjaters, Egils
Polyakov, Sergey
Jievaltas, Mindaugas
Luz, Murilo
Alekseev, Boris
Kuss, Iris
Le Berre, Marie-Aude
Petrenciuc, Oana
Snapir, Amir
Sarapohja, Toni
Smith, Matthew R.
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2020, 16 : 45 - 46
[49] Real-world clinical adverse events (AEs) among nonmetastatic castration-resistant prostate cancer (nmCRPC) patients treated with novel anti-androgen (AA) therapies: A retrospective database study.
Freedland, Stephen J.
Appukkuttan, Sreevalsa
Yao, Jianying
Du, Yuxian
Parkin, Jacqueline
Partridge, Jamie
Kong, Sheldon
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[50] Darolutamide and health-related quality of life in patients with non-metastatic castration-resistant prostate cancer: An analysis of the phase III ARAMIS trial
Smith, Matthew R.
Shore, Neal
Tammela, Teuvo L.
Ulys, Albertas
Vjaters, Egils
Polyakov, Sergey
Jievaltas, Mindaugas
Luz, Murilo
Alekseev, Boris
Kuss, Iris
Le Berre, Marie-Aude
Mohamed, Ateesha F.
Odom, Dawn
Bartsch, Jennifer
Snapir, Amir
Sarapohja, Toni
Fizazi, Karim
EUROPEAN JOURNAL OF CANCER, 2021, 154 : 138 - 146

← 1 2 3 4 5 →